Day One Biopharmaceuticals (DAWN) Projected to Post Earnings on Tuesday

Day One Biopharmaceuticals (NASDAQ:DAWN) is anticipated to release its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect Day One Biopharmaceuticals to post earnings of ($0.31) per share and revenue of $54.35 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%.The company had revenue of $53.72 million during the quarter, compared to analyst estimates of $49.81 million. On average, analysts expect Day One Biopharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN opened at $21.53 on Tuesday. Day One Biopharmaceuticals has a 1 year low of $5.64 and a 1 year high of $21.53. The stock has a 50 day simple moving average of $18.83 and a 200-day simple moving average of $12.67. The stock has a market cap of $2.22 billion, a PE ratio of -20.90 and a beta of -1.74.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DAWN. Weiss Ratings reissued a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. JonesTrading lowered Day One Biopharmaceuticals from a “buy” rating to a “hold” rating and increased their price target for the stock from $20.00 to $21.50 in a research report on Friday, March 6th. Wall Street Zen upgraded Day One Biopharmaceuticals to a “hold” rating in a research report on Saturday. Zacks Research lowered Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Finally, HC Wainwright restated a “neutral” rating and set a $21.50 price target (down from $22.00) on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 10th. One analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $23.29.

Insider Buying and Selling at Day One Biopharmaceuticals

In related news, insider Adam Dubow sold 6,395 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $74,182.00. Following the sale, the insider directly owned 72,694 shares in the company, valued at $843,250.40. This represents a 8.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael Vasconcelles sold 2,728 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $31,644.80. Following the completion of the transaction, the insider owned 4,397 shares in the company, valued at $51,005.20. The trade was a 38.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 36,461 shares of company stock worth $422,948 over the last 90 days. Company insiders own 6.20% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quarry LP acquired a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter valued at $49,000. Prudential Financial Inc. acquired a new stake in shares of Day One Biopharmaceuticals in the 2nd quarter valued at $69,000. Lazard Asset Management LLC acquired a new stake in shares of Day One Biopharmaceuticals in the 2nd quarter valued at $89,000. LPL Financial LLC acquired a new stake in shares of Day One Biopharmaceuticals in the 4th quarter valued at $102,000. Finally, Virtus Advisers LLC acquired a new stake in shares of Day One Biopharmaceuticals in the 4th quarter valued at $104,000. 87.95% of the stock is owned by institutional investors and hedge funds.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.